琥珀酸美托洛尔缓释片治疗扩张型心肌病的临床效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Metoprolol Succinate Sustained-release Tablets in the treatment of dilated cardiomyopathy. Methods A total of 74 patients with dilated cardiomyopathy who were admitted to our hospital from April 2018 to April 2019 were selected as the observation objects. According to the random number table method, the patients were divided into the conventional group (n=37, treated with Sacubitril Valsartan Sodium Tablets)and the study group (n=37, treated with Metoprolol Succinate Sustained-release Tablets on the basis of the conventional group). The heart rate (HR), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter(LVESD), and the number of pre-ventricular contractions in 24 h before and after treatment were observed and compared between the two groups and the incidence of arrhythmias and major adverse cardiac events (MACE) was compared between the two groups after 6 months of follow-up. Results After treatment, the HR, LVEDD and LVESD in the study group were lower than those in the conventional group, and the number of pre-ventricular contractions in 24 h in the study group was fewer than that in the conventional group, with statistically significant differences (P＜0.05). Following up for 6 months, the total incidence rates of arrhythmia and MACE in the study group were lower than those in the conventional group, with statistically significant differences (P＜0.05). Conclusion The use of Metoprolol Succinate Sustained-release Tablets in the treatment of dilated cardiomyopathy can effectively reduce the occurrence of arrhythmia, acute heart failure and other adverse events, improve the cardiac function of patients, and improve the long-term efficacy of patients.

Key words： Metoprolol Succinate Sustained-release Tablets Dilated cardiomyopathy Sacubitril Valsartan Sodium Tablets Cardiac function Arrhythmology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TIAN Zhi-huan

Cite this article:

TIAN Zhi-huan. Clinical effect of Metoprolol Succinate Sustained-release Tablets in the treatment of dilated cardiomyopathy[J]. 中国当代医药, 2020, 27(28): 55-57转61.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I28/55

[1]	张欢，刘雪丽，张红鸽，等.炙甘草汤联合替米沙坦、美托洛尔治疗扩张型心肌病合并室性期前收缩的临床疗效观察[J].延安大学学报（医学科学版），2019，17（1）：67-71.
[2]	康竹青.琥珀酸美托洛尔缓释片联合稳心颗粒治疗心肌梗死后室性心律失常效果观察[J].医药前沿，2019，9（5）：127.
[3]	曹庭家，周阳贞.卡维地洛和美托洛尔治疗扩张型心肌病心力衰竭的效果比较[J].基层医学论坛，2018，22（5）：639-640.
[4]	张娟，王吉利，谭月桂.曲美他嗪联合美托洛尔治疗老年扩张型心肌病合并心力衰竭患者的临床疗效[J].河北医药，2019，41（5）：728-730，734.
[5]	中华医学会心血管病学分会.心肌病诊断与治疗建议[J].中华心血管病杂志，2007，35（1）：5-16.
[6]	苏斌杰，俞飞虎，程劲松，等.沙库巴曲缬沙坦钠治疗扩张型心肌病临床疗效观察[J].心脑血管病防治，2019，19（6）：570-572.
[7]	谭倩.剂型对美托洛尔片治疗扩张型心肌病患者临床疗效的影响[J].医疗装备，2019，32（2）：112-113.
[8]	黎清.美托洛尔治疗扩张型心肌病的临床疗效及药理作用分析[J].临床合理用药杂志，2017，10（33）：35-36.
[9]	凡春红.琥珀酸美托洛尔缓释片与酒石酸美托洛尔片治疗老年不稳定型心绞痛的效果观察[J].海峡药学，2019，31（5）：155-156.
[10]	韩娟娟.琥珀酸美托洛尔缓释片联合稳心颗粒治疗心律失常患者的疗效观察[J].临床合理用药杂志，2019，12（11）：29-30.
[11]	张玲先.稳心颗粒联合美托洛尔治疗缺血性心律失常临床观察[J].社区医学杂志，2017，15（14）：68-69.
[12]	朱士元.胺碘酮联合琥珀酸美托洛尔治疗室性心律失常[J].中国卫生标准管理，2019，10（20）：88-90.
[13]	李跃通，李丽青，杨彬菲.琥珀酸美托洛尔缓释片治疗心肌梗死后室性心律失常效果分析[J].深圳中西医结合杂志，2019，29（3）：140-141.
[14]	陈鸣茵.酒石酸美托洛尔治疗扩张型心肌病的药理作用和临床效果[J].当代临床医刊，2019，32（4）：354-355.
[15]	谭卫群，刘琮，谢颖，等.美托洛尔联合丙种球蛋白对儿童扩张型心肌病心力衰竭的疗效观察[J].中国医药科学，2019，9（12）：60-62，85.
[16]	陈雪婷.琥珀酸美托洛尔缓释片联合稳心颗粒治疗心律失常的效果分析[J].心血管病防治知识，2018，（33）：58-59.
[17]	周沫，殷实，于艳丽，等.曲美他嗪联合美托洛尔治疗扩张型心肌病的疗效观察[J].广西医科大学学报，2018，35（1）：99-102.
[18]	卢百春.琥珀酸美托洛尔缓释片治疗扩张型心肌病39例临床观察[J].社区医学杂志，2017，15（2）：13-15.
[19]	朱凌华，朱明真.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的临床效果[J].中国当代医药，2018，25（29）：43-45.